Toboroz
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
NCT07441681· 3. fázis· NRG Oncology· Forrás
Contact: Laila A. Gharzai (principal investigator)
Toboroz
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
NCT07452458· 3. fázis· NRG Oncology· Forrás
Contact: Vinai Gondi (principal investigator)
Toboroz
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
NCT07195734· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jochen H. Lorch (principal investigator)
Toboroz
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
NCT07200830· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Michael Liu (principal investigator)
Toboroz
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
NCT06900595· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Mary F. Mulcahy (principal investigator)
Toboroz
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Emma Barber (principal investigator)
Toboroz
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NCT06686771· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Laila A. Gharzai (principal investigator)
Toboroz
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
NCT07061964· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Sean Sachdev (principal investigator)
Toboroz
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
NCT06769126· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: Young Kwang Chae (principal investigator)
Toboroz
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Eric D. Donnelly (principal investigator)
Toboroz
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
NCT07001748· 2/3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Brett L. Ecker (principal investigator)
Toboroz
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
NCT06649812· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Reem Karmali (principal investigator)
Toboroz
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· 3. fázis· NRG Oncology· Forrás
Contact: John P. Hayes (principal investigator)
Fut, nem toboroz
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
NCT06732401· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NCT06532279· 2. fázis· NRG Oncology· Forrás
Contact: Laila A. Gharzai (principal investigator)
Toboroz
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
NCT06577441· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Yasmin Abaza (principal investigator)
Toboroz
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT06616584· 2/3. fázis· SWOG Cancer Research Network· Forrás
Contact: Young Kwang Chae (principal investigator)
Toboroz
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
NCT06672146· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Himachandana Atluri (principal investigator)
Toboroz
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
NCT06498635· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Young Kwang Chae (principal investigator)
Toboroz
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: David VanderWeele (principal investigator)
Toboroz
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NCT06500481· 3. fázis· NRG Oncology· Forrás
Contact: Vinai Gondi (principal investigator)
Toboroz
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962· 3. fázis· Children's Oncology Group· Forrás
Contact: Shira N. Dinner (principal investigator)
Toboroz
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
NCT06475989· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Jochen H. Lorch (principal investigator)
Fut, nem toboroz
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
NCT05647265· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Young Kwang Chae (principal investigator)
Toboroz
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
NCT06470243· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Maha H. Hussain (principal investigator)
Toboroz
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: Young Kwang Chae (principal investigator)
Toboroz
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Yasmin Abaza (principal investigator)
Fut, nem toboroz
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
NCT06538038· PrECOG, LLC.· Forrás
Toboroz
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Seth M. Pollack (principal investigator)
Fut, nem toboroz
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
NCT06115499· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: Young Kwang Chae (principal investigator)
Toboroz
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Aparna Kalyan (principal investigator)
Toboroz
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06203600· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Aparna Kalyan (principal investigator)
Toboroz
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jessica K. Altman (principal investigator)
Fut, nem toboroz
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT05564403· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: David VanderWeele (principal investigator)
Toboroz
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
NCT05773274· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Al B. Benson (principal investigator)
Fut, nem toboroz
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
NCT05863351· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Toboroz
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· 3. fázis· NRG Oncology· Forrás
Contact: Sean Sachdev (principal investigator)
Fut, nem toboroz
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT05554367· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Lisa E. Flaum (principal investigator)
Fut, nem toboroz
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828· ECOG-ACRIN Cancer Research Group· Forrás
Toboroz
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Lisa E. Flaum (principal investigator)
Fut, nem toboroz
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
NCT05710406· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996· 3. fázis· NRG Oncology· Forrás
Contact: Mohamed E. Abazeed (principal investigator)
Toboroz
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: William J. Gradishar (principal investigator)
Fut, nem toboroz
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
NCT05694871· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jane N. Winter (principal investigator)
Toboroz
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
NCT05642572· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: Young Kwang Chae (principal investigator)
Showing 50 of 158.